PRACTICAL SCENARIO
 
Investigators from the Instituto Nacional de Enfermedades Respiratorias (INER, National Institutes of Respiratory Diseases) in Mexico aimed to analyze the burden of respiratory diseases in the adult Mexican population over a 30-year period. They needed trustworthy information about the incidence and mortality of several diseases over a large period and opted to use data from The Global Burden of Diseases (GBD) initiative. They found that respiratory diseases are responsible for approximately 30% of deaths among adults in Mexico, and that mortality due to chronic respiratory diseases has been rising since 1990 across both genders.(1)
 
THE GBD INITIATIVE
 
The GBD initiative, launched in 1991 by the World Bank and the World Health Organization, is a comprehensive framework that generates standardized health information worldwide.(2) It is used to identify health disparities and priorities, inform evidence-based public health decisions, and measure their impact. Managed by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington in the United States, the GBD’s leading articles have been published in Lancet.(3)
 
The GBD’s data allows comparisons across different regions, countries, populations, genders, and age groups from 1990 to 2021. Before the GBD, no consistent global reporting of the prevalence and mortality of diseases existed, thus several countries, especially low- and middle-income countries, lacked accurate health statistics.
 
The GBD project has been instrumental in promoting innovation in reporting disease impact. It introduced the concept of disability-adjusted life years (DALYs), a comprehensive measure of health that combines years of life lost by premature death (YLL) and years of life lived with disability (YLD). This approach, which considers both quantity (mortality) and quality (morbidity) of life, has significantly expanded our understanding of disease burden.
 
The GDB is easily accessible to clinicians, clinical researchers, epidemiologists, public health professionals, politicians, and the general public. It can be consulted online and includes tables, graphs, and open-access downloadable data. However, the GBD does not provide estimates for all diseases or risk factors, only for the most relevant ones, although the number has been increasing. Chart 1 shows the main characteristics of the GBD.

 
The GBD project covers a range of respiratory diseases and their risk factors.(1) These include chronic respiratory diseases, such as COPD, interstitial lung diseases, sarcoidosis, pneumoconiosis, and asthma. It includes respiratory infections, such as COVID-19, such as lower and upper respiratory infections, and tuberculosis, and respiratory neoplasms, such as lung and head-and-neck cancers. Commonly reported risk factors for respiratory diseases include air pollution (outdoor particulate matter and ozone, household air pollution, occupational exposures), active and passive tobacco smoking, and infections.
 
The GBD has been regularly updated since 1990, and most data are available at the Global Health Data Exchange website without cost (GHDx, https://ghdx.healthdata.org). It is a clinician-friendly source of information, including tables, graphs, and illustrations on the status of disease burden, which are key for presentations and introductions to thesis or manuscripts.
 
KEY MESSAGES
 
The GBD is an open-access reliable database used to describe and compare estimates of respiratory health indicators across countries and regions over time.
 
It is helpful for clinicians, epidemiologists, and public health officers.
 
Empiric validation of the estimates should be sought, especially for areas lacking sufficient health information.
 
REFERENCES
 
1.           Perez-Padilla JR, Thirión-Romero I, Robles-Hernández R, Cagney J, Razo C, Ríos-Blancas MJ. Respiratory diseases in Mexico: analysis from the Global Burden of Disease study 2021. Gac Med Mex. 2023;159(6):582-595. https://doi.org/10.24875/GMM.M24000840
2.           Murray CJL. The Global Burden of Disease Study at 30 years. Nat Med. 2022;28:2019-2026. https://doi.org/10.1038/s41591-022-01990-1
3.           GBD 2021 Diseases and Injuries Collaborators. Global incidence, preva-lence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133-2161. https://doi.org/10.1016/S0140-6736(24)00757-8